Bayer wins U.S. priority review of the drug against metastatic prostate cancer

Bayer's Nubeqa drug won priority review status from the U.S. Food and Drug Administration, as the German drugmaker seeks to widen the use of the prostate cancer drug from an early disease stage to metastatic cases.

The priority status was granted as the U.S. regulatory body accepted Bayer's supplemental New Drug Application (sNDA) for the use of Nubeqa, jointly developed with Finnish drugmaker Orion, against metastatic hormone-sensitive prostate cancer, Bayer said in a statement on Tuesday.

(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)